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OBJECTIVE: Severe energy restriction in the treatment of obesity is limited by catabolism of body protein stores and,
consequently, loss of lean as well as fat tissue. Growth hormone (GH), whose secretion is markedly impaired in
obesity, is endowed with both lipolytic and protein anabolic properties. The aim of this study was to verify the effects
of GH administration on body composition, plasma leptin levels and energy metabolism in obese patients undergoing
severe dietary restriction.
DESIGN: Single-blind placebo-controlled study. Twenty obese women were fed a diet of 41.86 kJ/kg ideal body weight
(IBW) daily for 4 weeks: 10 of them were randomly assigned to a 4 week treatment with biosynthetic GH (rhGH,
Saizen, Serono, Rome, Italy), 1 U/kg IBW/week in daily subcutaneous injections; the other 10 patients, matched for
age and BMI, received vehicle only.
SUBJECTS: Twenty women with simple obesity (age: 25.4 1.07 y, BMI: 35.9 0.35 kg/m2).
MEASUREMENTS: Plasma IGF-I and leptin, serum markers of bone turnover (serum bone isoenzyme of alkaline
phosphatase, osteocalcin and urinary hydroxyproline), nitrogen balance, body composition (by DEXA), and resting
energy expenditure (REE, by indirect calorimetry) were evaluated at baseline and after 4 weeks.
RESULTS: Mean IGF-I plasma levels, not in¯uenced by energy restriction in patients receiving placebo, displayed a
signi®cant increase in the group treated with rhGH. The mean weight reduction and fat mass loss were not
signi®cantly different in the two groups (6.0 0.51 vs 7.2 0.30 kg, NS, and 5.36 0.460 vs 4.28 0.572 kg, NS, with
rhGH and placebo, respectively). Likewise, plasma leptin levels decreased signi®cantly in weight-reduced subjects
receiving either rhGH (from 16.2 2.37 to 6.4 0.39 ng/ml, P< 0.05) or placebo (from 14.3 2.55 to 7.7 3.77 ng/ml,
P< 0.05). On the contrary, the mean decrease of lean body mass (LBM) was signi®cantly lower in the GH-treated
patients than in those receiving vehicle (1.52 0.60 vs 3.79 0.45 kg, P< 0.05). In keeping with these ®ndings, the
mean daily nitrogen balance was signi®cantly less negative in the GH-treated subjects than in the vehicle-injected
patients (mean of the 4 week daily urine collections 7185.7 40.33 vs7363.9 55.47 mmol/d, P< 0.05, respectively).
Further, a signi®cant reduction of mean REE was recorded in the energy-restricted placebo-treated patients (from
8807 498 to 7580 321 kJ/24 h, P< 0.05), but not in the patients receiving rhGH (from 8367 580 to 8903 478 kJ/
24 h, NS). Actually, when corrected for LBM, REE was even increased by GH administration (from 197.9 11.76 to
219.3 9.87 kJ/kg LBM/24 h, P< 0.05), whereas it was unchanged in the placebo group (from 201.7 13.85 to
190.0 9.87 kJ/kg LBM/24 h, NS). A tendency of serum markers of bone turnover to increase was observed in the
patients treated with rhGH, however with no changes in bone mineral content and density.
CONCLUSION: rhGH treatment, though unable to enhance diet-induced weight and fat mass reduction, was effective
in stimulating IGF-I production and conserving LBM and increasing its energy metabolism even in the presence of
severe energy restriction.
Keywords: obesity; growth hormone treatment; body composition; plasma leptin; resting energy expenditure;
metabolic and hormonal parameters
Introduction
A major drawback of energy restriction for the treat-
ment of obesity is represented by catabolism of body
proteins and negative nitrogen balance. As a conse-
quence, weight-reducing diets result in loss of lean as
well as fat tissue.1 Since protein-supplemented diets
produce only a modest nitrogen sparing,2 more effec-
tive tools are needed to preserve protein stores and
lean body mass (LBM), which is the main determinant
of resting energy expenditure (REE),3 during dietary
restriction.
Growth hormone (GH) is endowed with both lipo-
lytic and protein anabolic properties.4–7 Its action is
mostly mediated by insulin-like growth factor I (IGF-
I), whose synthesis is greatly influenced by the nutri-
tional status.8 In obesity spontaneous as well as
pharmacologically triggered GH secretion is greatly
impaired while peripheral levels of IGF-I are only
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inconstantly blunted. In a few trials, treatment with
high-dose GH appeared effective, when compared to
placebo, in conserving LBM in energy-restricted
obese subjects,9–12 and in reducing body fat in
obese women during a weight-maintaining diet.13 In
addition, GH administration to GH-deficient adults is
associated with an increase in REE, likely through the
enhancement of peripheral conversion of thyroxine
(T4) to triiodothyronine (T3).14,15 GH treatment was
also found capable of increasing serum markers of
bone turnover in normal volunteers16 and GH-defi-
cient adults17 and, in the latter, bone mineral density
in the long term.17
A decrease in plasma leptin concentrations has been
described in obese patients after diet-induced weight
loss18 and in GH-deficient adults after GH substitution
therapy.19 The impact of the combination of GH
treatment and energy restriction on peripheral leptin
levels in obese patients is unknown.
The present study was aimed at evaluating the
effects of GH treatment on weight loss, body com-
position and plasma leptin levels in a group of obese
subjects undergoing severe dietary restriction.
Another objective was to establish the influence of
severe hypocaloric diet, associated or not with GH
administration, on circulating levels of IGF-I.
Finally, we investigated the effects of GH adminis-
tration on REE, glucose and lipid metabolism, bone
turnover and bone mineral content (BMC) and den-
sity (BMD).
Methods
Subjects
Twenty obese women aged 25.4 1.0 7 (mean stan-
dard error) years with a body mass index (BMI,
calculated as weight divided by height squared, kg/
m2) of 35.9 0.35 gave their informed consent to
participate in this study, which was approved by the
Ethical Committee of our Institution. The subjects
were in good general health and a medical evaluation
including history, physical examination and routine
blood chemistry revealed no abnormalities. Thyroid
function was normal. None of the patients was taking
any medications or exercising regularly during the 3
months preceding the study. During the same period
of time, their body weight had been stable.
The subjects were studied as inpatients in our
department. They were fed a balanced diet of
41.86 kJ/kg ideal body weight (IBW) daily for 4
weeks. Energy was supplied in a ratio of 50% carbo-
hydrate (73.3 g), 30% fat (18.2 g) and 20% protein
(27.9 g).
Care was exercised to maintain, during hospitalisa-
tion, the usual daily energy expenditure; this was
accomplished by individual diary records and pro-
grams of physical activity.
According to a single-blind design, 10 patients were
randomly assigned to a 4 week treatment with biosyn-
thetic GH (rhGH, Saizen, Serono, Rome, Italy) 1 U/kg
IBW/week in daily subcutaneous injections given at
8 pm. The other 10 patients, matched for age and
BMI, received vehicle only.
Measurements
The subjects were weighed at the same time each
morning before breakfast. Pulse rate and blood pres-
sure were recorded daily. Circulating concentrations
of glucose, insulin, free fatty acids (FFA), IGF-I,
leptin, calcium, phosphate, bone isoenzyme of alkaline
phosphatase (AP), osteocalcin, free thyroid hormones
(fT4 and fT3), cholesterol and triglycerides were
measured on blood samples collected after an over-
night fast, under baseline conditions and at the end of
the study. Twenty-four-hour urine samples were col-
lected daily for nitrogen balance, and at baseline and
after study completion for the estimation of calcium
and hydroxyproline. Completeness of the collections
was monitored by quantitating urinary creatinine
excretion.20 Urinary 24-h creatinine and urea nitrogen
excretion were determined using autoanalyser mod-
ifications of published methods that measure both urea
and ammonia nitrogen;20,21 24-h nitrogen balance was
calculated by subtracting the urinary urea nitrogen
plus 4 g nitrogen from the total nitrogen ingested.22,23
Serum concentrations of glucose, calcium, phosphate,
AP, cholesterol and triglyceride were measured by
routine assays. Serum insulin concentrations were
estimated by fluoro-enzymatic-immunoassay (FEIA)
using a commercial kit (Tosoh, Tokyo, Japan); the
normal range for insulin is 3.96–146.4 pmol=l. Plasma
concentrations of IGF-I were measured, after extrac-
tion with acid-ethanol, by RIA using a commercial kit
(Nichols Institute Diagnostic, San Juan de Capistrano,
CA, USA); the normal range for IGF-I is, for females
aged 16–26 years, 182–780 ng=ml. Plasma leptin was
determined by RIA using a human leptin RIA kit
(Linco Research, St. Charles, MO, USA). In our
laboratory the mean value for plasma leptin obtained
in 23 normal weight (BMI 23.6 0.57) age and sex
matched blood donors was 6.8 0.93 ng/ml. Serum
osteocalcin was measured by RIA using a commercial
kit (Cis Biointernational, Gif sur Yvette, France); the
normal range is 10.7–24.7 ng=ml. The assay of FFA
was performed by an enzymatic method using
reagents purchased from Boehringer Mannheim
Yamanouchi (Tokyo, Japan); the FFA normal range
is 250–270 mEq=l. The urinary concentrations of
calcium, phosphate and hydroxyproline were mea-
sured by colorimetric assays, Boehringer Mannheim
(Germany) for the first two parameters and by high-
performance liquid chromatography (HPLC) for the
third one. The normal ranges are 2.49–7.48 mmol=d
for urinary calcium, 12.91–32.29 mmol=d for urinary
phosphate and 76.26–305.0 mmol=d=m2 for urinary
hydroxyproline. The analysis of body composition for
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the evaluation of fat mass, LBM, BMC and BMD was
performed at the beginning and at the end of the 4th
week of the study by dual energy X-ray absorptiome-
try (DEXA, Hologic QDR-1000, Waltham, MA,
USA). LBM comprises both muscle tissue and non
muscle fat-free tissue (including the water space),
with the exclusion of BMC. BMC and BMD are
expressed as subtotal values, i.e. whole body minus
head. REE was assessed by indirect calorimetry, after
an overnight fast and a 30 min bed rest; patients were
studied under basal conditions and weekly during the
treatment. A computerized open circuit system was
employed to measure gas exchange across a 25 l
canopy (Sensor Medics 2900, Yorba Linda, CA,
USA). The values were expressed as kJ/24 h and,
when REE was corrected for LBM, as kJ/kg LBM/24 h.
Statistical analysis
Data are expressed as mean standard error, unless
stated otherwise. Statistical analysis was performed
using the Wilcoxon and Mann-Whitney non-param-
etric tests, as appropriate. A P value less than 0.05
was considered statistically significant.
Results
Mean IGF-I plasma concentrations were not influ-
enced by energy restriction in patients receiving
placebo (from 205.5 40.6 to 239.6 38.9 ng/ml,
NS), whereas they displayed a significant increase in
the group tested with rhGH (from 240.7 21.8 to
319.4 30.0 ng/ml, P< 0.01).
The anthropometric parameters of all subjects are
reported in Table 1. The mean weight reduction and
fat mass loss were not significantly different in the
two groups, although the GH-treated patients lost less
weight and more fat mass than the placebo-treated
patients (6.0 0.51 vs 7.2 0.30 kg, NS, and 5.36
0.460 vs 4.28 0.572 kg, NS, respectively). Plasma
leptin concentrations were significantly decreased in
weight-reduced subjects following either GH or pla-
cebo administration (Table 2). Like fat mass loss,
leptin decrease was slightly greater in GH than in
placebo-treated patients. On the contrary, the mean
decrease of LBM was significantly lower in the GH-
treated patients than in those receiving vehicle
(1.52 0.60 vs 3.79 0.45 kg, P< 0.05). During the
41.86 kJ/kg IBW diet, mean nitrogen balance was less
negative in the GH-treated patients compared to the
vehicle-injected women (mean of the 4 week daily
urine collections 7185.7 40.3 vs 7363.9 55.4
mmol/d, P< 0.05, respectively).
A significant reduction of mean REE was observed
in the energy-restricted placebo-treated patients (from
8807 498.9 to 7580 321.9 kJ/24 h, P< 0.05),
whereas the same parameter was not modified in the
patients receiving rhGH (from 8367 580 to
8903 478 kJ/24 h, NS). Actually, when corrected
for LBM, REE was even increased by GH admin-
istration (from 197.9 11.76 to 219.3 9.87 kJ/kg
LBM/24 h, P< 0.05), whereas it was unchanged in
the placebo group (from 201.7 13.85 to 190.0
9.87 kJ/kg LBM/24 h, NS).
Table 2 Effects of biosynthetic growth hormone treatment on metabolic and hormonal parametersa
Placebo GH
Baseline After 4 weeks Baseline After 4 weeks
Glucose (mmol/l) 4.56 0.105 4.55 0.149 4.660.144 4.64 0.188
Insulin (pmol/l) 76 13.8 49 6.6** 9919.8 105 14.4**
Total cholesterol (mmol/l) 5.07 0.212 3.83 0.173* 4.520.338 3.68 0.201*
Triglycerides (mmol/l) 1.19 0.230 1.04 0.073 1.340.163 1.33 0.099
FFA (mEq/l) 471.8 55.3 862.6 110.5* 545.3121.7 982 176.9*
FT4 (pmol/l) 10.8 0.67 11.9 0.74 11.60.78 10.4 0.95
FT3 (pmol/l) 5.3 0.24 4.9 0.35 5.30.26 5.36 0.39
Leptin (ng/ml) 14.3 2.55 7.7 3.77* 16.22.37 6.4 0.39*
*P<0.05 vs baseline. **P< 0.05 between groups. aMean standard error.
Table 1 Effects of biosynthetic growth hormone treatment on anthropometric parameters and body
composition determined by dual energy X-ray absorptiometry (DEXA)a
Placebo GH
Baseline After 4weeks Baseline After 4 weeks
Body weight (kg) 93.6 0.80 86.5 0.67* 93.02.64 87.02.35*
BMI (kg/m2) 36.3 0.49 33.6 0.61* 35.30.98 33.00.93*
Fat mass (kg) 47.02 1.44 42.73 1.66* 49.072.10 43.712.42*
% Fat mass loss ± 9.1 1.34 ± 10.91.40
Lean mass (kg) 43.83 1.15 40.04 1.14* 42.141.42 40.611.29*
% Lean mass loss ± 8.6 1.01 ± 3.51.39**
*P<0.05 vs baseline. **P<0.05 between groups. aMean standard error.
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As reported in Table 2, a significant decrease in
total cholesterol and increase in FFA, of comparable
magnitude in the two groups of patients, were
observed. Serum triglycerides were substantially
unchanged in both groups, and the same held true
for glucose and thyroid hormones. Diet tended to
reduce plasma insulin, although not reaching statisti-
cal significance, in vehicle injected patients, but not in
those receiving GH. Although no significant changes
in insulin concentrations were detected within each
treatment group even when considering delta values,
i.e. differences between baseline and final concen-
trations (727 18.3 vs 7 23.3 pmol/l, NS, in the
placebo- and GH-treated patients, respectively), the
absolute post-treatment insulin values were signifi-
cantly different between the two groups (49 6.6 vs
105 14.4 pmol/l, P< 0.05, after placebo and after
rhGH, respectively).
Serum AP bone isoenzyme increased significantly in
GH-treated patients, who also displayed a moderate
rise in serum osteocalcin and urinary hydroxyproline
(Table 3). None of these parameters was modified in
subjects receiving vehicle. While these latter showed a
significant decrease in urinary calcium, the same para-
meter was unchanged in GH-treated patients. No sig-
nificant changes in serum calcium and phosphate, as
well as in subtotal BMC and BMD, were recorded in
the two groups of obese patients along the study period.
Discussion
Nutritional status plays a central role in the regulation
of IGF-I production and hence of most of the biolo-
gical actions of GH. IGF-I plasma concentrations are
low in malnourished patients8 while, in normal sub-
jects, fasting lowers plasma IGF-I levels under basal
conditions24 and in response to GH administration.25
In obese subjects, the IGF-I production induced by
exogenous GH is gradually impaired by the progres-
sive limitation of energy intake.9–11 The present study
has shown that a number of biological actions of GH,
i.e. stimulation of IGF-I synthesis, sparing of body
proteins, enhancement of bone turnover and REE, are
maintained in obese patients in conditions of severe
energy restriction. This finding is in line with the
observation that in energy-restricted obese patients the
administration of GH in increasing dosage results in a
dose-dependent rise of plasma IGF-I levels. A sig-
nificant IGF-I increase after prolonged GH adminis-
tration has been reported, under experimental
conditions similar to ours, by Drent et al.26 These
authors, however, failed to demonstrate changes in
body composition by bioimpedance analysis (BIA). In
our patients the IGF-I increase following GH treat-
ment was accompanied by evident metabolic effects,
chiefly by sparing of LBM estimated by DEXA. This
finding is in keeping with the improvement of nitro-
gen balance observed in the present study and in other
series of energy-restricted obese patients treated with
GH,9,10,12 and demonstrates that GH anabolic proper-
ties are retained even when energy intake is markedly
reduced. The lack of changes in IGF-I levels observed
in our energy restricted placebo-treated patients fits in
well with the resistance of obese patients to dietary
restriction in terms of IGF-I reduction.8
In our patients, the combination of GH treatment
and energy restriction induced a greater, though not
statistically significant, fat mass loss compared to diet
alone. Accordingly, leptin was reduced to a slightly
greater extent by GH (60.5%) than by placebo admin-
istration (46.2%), in agreement with the data reported
in GH deficient GH-treated adults.19 This is consistent
with the failure of GH treatment to significantly
enhance diet-induced fat loss in obese patients
observed in other studies9,10,12 with the exception of
a recent one27 in which the patients received an energy
intake (62.79 kJ/kg IBW daily) 50% higher than the
one adopted in our protocol. A more striking decrease
in body fat, especially at visceral level,28 is well
documented in obese patients receiving GH while on
a normocaloric diet.13,28,29
The observation of a smaller LBM loss in GH-
treated women in spite of no significant differences in
changes of body weight and fat mass between the two
groups may not be in contradiction; in fact, statisti-
cally insignificant but not negligible variations in
parameters of body composition may account for the
apparent discrepancy of these results. The good cor-
respondence between body weight loss estimated by
Table 3 Effects of biosynthetic growth hormone treatment on bone metabolisma
Placebo GH
Baseline After 4 weeks Baseline After 4 weeks
Serum calcium (mmol/l) 2.2 0.04 2.30.07 2.1 0.04 2.3 0.02
Serum phosphate (mmol/l) 1.0 0.06 1.20.10 1.1 0.06 1.3 0.09
Bone isoenzyme of alkaline phosphatase (% of total) 22.8 6.59 325.4 26 3.5 41.6 5.42*
Osteocalcin (ng/ml) 20.7 1.24 18.42.99 22.2 4.45 34.7 12.02
Urinary calcium (mmol/d) 2.8 0.27 2.10.41* 2.0 0.27 2.4 0.57
Urinary phosphate (mmol/d) 16.1 3.22 22.62.58 19.3 3.87 22.7 2.76
Urinary hydroxyproline (mmol/d/m2) 133.4 33.70 152.550.33 89.2 20.20 199.8 60.85
BMD (g/cm2) 1.04 0.013 1.060.018 1.00 0.027 1.00 0.03
BMC (g) 2652.3 177.66 2640.1142.0 2451.2 111.05 2458.9 110.3
*P<0.05 vs baseline. aMean standard error.
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DEXA (sum of fat mass and LBM losses) and body
weight estimated using a balance gives consistency to
the data.
GH treatment has been found to increase REE in
adult patients with GH deficiency.15,30,31 In one
study15 the increase in REE was positively correlated
with the increase in T3 serum levels, caused by the
GH-induced peripheral conversion of T4 to T3 itself.
A significant increase in REE, recognizable even
when REE was corrected for LBM and not correlated
with thyroid hormone concentrations, was also
observed in obese women treated with rhGH for five
weeks but not following a hypocaloric diet.29 In the
present experience, conducted in severely energy-
restricted obese women, GH administration appeared
able not only to prevent the diet-induced reduction of
REE but also to significantly increase the value of
REE corrected for unit of LBM. The latter finding
suggests that in the GH-treated patients the mainte-
nance of a REE similar to the pre-diet value was due
not only to the sparing of LBM, but to the enhance-
ment of energy metabolism of LBM itself. These
effects did not appear to be correlated with changes
in thyroid hormone concentrations.
Since DEXA is unable to distinguish between
muscle tissue and water, the possibility that the fluid
retentive action of GH has contributed to the smaller
decrease in LBM observed in the patients treated with
the hormone should be considered. However, the
hypothesis of an actual preservation of muscle mass
by GH treatment is supported by the less negative
nitrogen balance observed in the treated patients and
by the maintenance, in the same women, of baseline
values of REE, whose main determinant is muscle
tissue and not water. Furthermore, in experimental
conditions similar to ours, the body water changes
estimated by BIA were found to be not different
between GH- and diet only-treated obese patients by
Drent et al.26
In our patients, the administration of rhGH did not
affect the diet-induced modifications of serum lipid
profile nor did it influence serum glucose levels.
However, the decrease in insulin levels seen in
energy-restricted vehicle-injected patients was com-
pletely prevented by GH treatment in patients under-
going the same diet regimen. These findings confirm
the GH-induced worsening of carbohydrate metabo-
lism usually seen in both normal man32 and GH
deficient subjects.33
The relevance of GH in the physiology of bone
remodelling is well recognized with the GH/IGF-I
system promoting bone turnover, with a prevalence of
formation over reabsorption and a positive net balance
at each remodelling site. In fact, long-term adminis-
tration of rhGH has been shown to significantly
improve bone mineralization in GH deficient
adults,34 who display reduced BMD and increased
risk for fracture.35 In the present study, a tendency of
the serum markers of bone turnover (AP bone isoen-
zyme, serum osteocalcin and urinary hydroxyproline)
to increase was observed in obese patients treated with
rhGH but not in energy-restricted placebo-treated
patients. Moreover, rhGH treatment appeared to pre-
vent, in our obese women, a diet-related reduction of
urinary calcium. This might be due to the early
activation of bone turnover induced by the hormone
or to an enhanced intestinal calcium absorption sec-
ondary to increased vitamin D activation. In any case,
no changes in subtotal BMC and BMD were recorded
in the two groups of patients, possibly due to the short
observation period.
In conclusion, rhGH treatment, if performed at
adequate doses, appears to be effective in obese
patients when associated with severely hypocaloric
diets. The major benefits are represented by reduction
of the LBM loss which follows energy restriction and
improvement of LBM metabolic efficiency. These
results encourage additional studies aimed at evaluat-
ing whether the administration of less expensive
compounds capable of stimulating endogenous GH
release is equally effective in improving the outcome
of severe dietary restriction in obesity.
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